T2 Level 97 102 cells
T5 Gene 1128 1131 PSA
T6 Condition 678 692 cancer patient
T7 Organism 339 346 patient
T8 Level 119 123 cell
T9 Condition 1171 1175 CTCs
T11 Level 1690 1704 megakaryocytes
T12 Condition 224 227 CTC
T13 Organism 339 347 patients
T14 Condition 1710 1716 cancer
T15 Condition 328 331 CTC
T17 Condition 1778 1784 cancer
T19 Condition 1635 1638 CTC
T20 Gene 562 571 serum PSA
T21 Level 659 673 megakaryocytes
T22 Gene 849 864 genomic regions
T23 Condition 1041 1051 metastases
T24 Gene_or_gene_product 1611 1615 ≥2.0
T25 Condition 1210 1220 metastases
T26 Level 119 124 cells
T27 Condition 353 368 prostate cancer
T28 Condition 1394 1400 cancer
T29 Condition 1811 1818 predict
T30 Condition 1203 1209 cancer
T31 Condition 104 107 CTC
T32 Level 97 101 cell
T33 Gene 1000 1003 CK+
T34 Gene 1004 1008 VIM+
T37 Condition 909 913 CTCs
T38 Condition 173 188 prostate cancer
T39 Gene 1165 1175 CD45− CTCs
T40 Level 79 102 circulating tumor cells
T42 Gene 1156 1159 CK+
T43 Level 1516 1530 megakaryocytes
T44 Condition 543 550 predict
T46 Condition 1203 1220 cancer metastases
T47 Gene 903 913 CD45− CTCs
T48 Condition 1819 1833 monitor cancer
T49 Condition 362 368 cancer
T51 Gene 1160 1164 VIM+
T52 Gene 621 624 PSA
T53 Condition 1082 1085 CTC
T55 Condition 1082 1086 CTCs
T56 Condition 441 463 disease aggressiveness
T57 Intervention 1104 1111 samples
T58 Condition 1015 1019 CTCs
T59 Level 1495 1511 mesenchymal CTCs
T60 Gene 1009 1019 CD45− CTCs
T61 Condition 1507 1510 CTC
T62 Gene 880 892 cytokeratin 
T63 Condition 1015 1018 CTC
T64 Protein 734 737 Cox
T66 Level 785 796 CD45− cells
T68 Level 1304 1318 megakaryocytes
T69 Level 1292 1318 circulating megakaryocytes
T71 Gene 629 639 EMTing CTC
T72 Condition 1189 1196 predict
T74 Condition 1376 1400 advanced prostate cancer
T75 Condition 1171 1174 CTC
T76 Intervention 769 778 vimentin 
T77 Gene 898 902 VIM+
R1 Relation Arg1:T2 Arg2:T32
